L3VLUP
ProSign in

INSM · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

INSMLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • INSM
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterINSMLLY
Q3 20209 holders, $1.2bn33 holders, $14.1bn
Q4 20208 holders, $1.0bn29 holders, $17.3bn
Q1 20216 holders, $816m24 holders, $23.0bn
Q2 20216 holders, $800m24 holders, $27.8bn
Q3 20217 holders, $803m31 holders, $29.9bn
Q4 20217 holders, $760m31 holders, $34.7bn
Q1 20228 holders, $680m24 holders, $35.3bn
Q2 20227 holders, $566m33 holders, $42.7bn
Q3 202210 holders, $379m31 holders, $43.4bn
Q4 20228 holders, $360m31 holders, $46.6bn
Q1 20236 holders, $282m33 holders, $44.3bn
Q2 20236 holders, $353m37 holders, $59.6bn
Q3 20237 holders, $415m44 holders, $67.6bn
Q4 20238 holders, $539m45 holders, $73.6bn
Q1 20248 holders, $437m41 holders, $95.3bn
Q2 202416 holders, $2.2bn43 holders, $110bn
Q3 202418 holders, $2.3bn45 holders, $107bn
Q4 202414 holders, $1.6bn46 holders, $93.9bn
Q1 202514 holders, $1.9bn42 holders, $98.4bn
Q2 202523 holders, $3.7bn43 holders, $93.2bn
Q3 202520 holders, $5.8bn39 holders, $86.7bn
Q4 202519 holders, $6.6bn41 holders, $123bn
Q1 202619 holders, $7.0bn39 holders, $106bn
Q2 202621 holders, $5.0bn44 holders, $132bn
INSM

Insmed Inc

Holders
18
Reported value
$2.3bn
Buyers
10
Sellers
10

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
45
Reported value
$107bn
Buyers
24
Sellers
22

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only INSM (3)

Farallon Capital Management LLC, Point72 Asset Management LP, Soros Fund Management LLC

Only LLY (30)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Susquehanna International Group LLP, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →